-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, accounting for about 3.
3% of all cancer cases
.
Squamous cell carcinoma of the head and neck is generally treated with concurrent radiotherapy and chemotherapy after surgery, and traditional chemotherapy drugs often cause a variety of side effects
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, accounting for about 3.
Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
.
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC
Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
research summary
research summaryThe objective response rate (ORR) can be extracted from 6 studies, and the comprehensively calculated ORR is 86.
3% (95%CI, 60.
3-96.
3; I 2 = 85.
2, p <0.
001)
.
Analysis of the location of the primary tumor showed that the ORR of oral cancer and laryngeal cancer was significantly different (46% vs 97%, I 2 = 67.
The objective response rate (ORR) can be extracted from 6 studies, and the comprehensively calculated ORR is 86.
ORR, CBR and LCR-3
ORR, CBR and LCR-3Oral cancer and laryngeal cancer ORR, CBR, LCR-3, OS-3 and grade 3/4 adverse events
Oral cancer and laryngeal cancer ORR, CBR, LCR-3, OS-3 and grade 3/4 adverse events12 studies can calculate the 3-year OS, and the comprehensive 3-year OS is 84.
0% (95% CI, 71.
4-91.
7; I 2 = 79.
6, p <0.
001)
.
There was a statistically significant difference in OS-3 between oral cancer and laryngeal cancer (60.
12 studies can calculate the 3-year OS, and the comprehensive 3-year OS is 84.
OS-3 and grade 3/4 adverse events
OS-3 and grade 3/4 adverse eventsIn summary, the meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
In summary, the meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
Original source:
Shih, H.
Shih, H.
-S.
; J hou, H.
-J.
; Ou, Y.
-H.
; et al.
The Efficacy and Adverse Events in Patients with Head and Neck Cancer Following Radiotherapy Combined with S-1 Therapy: A Meta-Analysis.
Cancers 2021, 13, 2971.
https://doi.
org/ 10.
3390/cancers13122971.
Leave a message here